SLC5A2 and chronic kidney disease: Accordingly, concerns about the safety and efficacy of initiating SGLT2 inhibitors during hospitalization for acutely decompensated heart failure (ADHF)—including their renal effects—are minimal, even in patients with pre‐existing hypotension or chronic kidney disease (CKD).11